RxDoctor Payments Data

Samuel Olaleye, MD

Internal Medicine · Newton, MSNPI 1821006644

Payments from drug & device makers

$4,231in general payments, 2019–2025

Across 182 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$707
  • Johnson & Johnson$585
  • Boehringer Ingelheim$525
  • AstraZeneca$487
  • Bayer$223
  • plus $659 from 7 others

What the payments were for

  • Food & beverage$3,96294%
  • Education$2696%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,231 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$48,714
Medicare patients
88
Services billed
774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide668$753,008
JardianceEmpagliflozin219$197,781
OzempicSemaglutide161$176,720
Synjardy XrEmpagliflozin/Metformin Hcl168$96,016
TrulicityDulaglutide75$85,320
LinzessLinaclotide79$46,846
Tresiba Flextouch U-200Insulin Degludec49$43,203
KerendiaFinerenone37$32,028
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$23,474
EliquisApixaban31$23,057
FarxigaDapagliflozin Propanediol30$21,701
XareltoRivaroxaban15$11,123
MyrbetriqMirabegron23$10,226
GlyxambiEmpagliflozin/Linagliptin12$7,057
Trijardy XrEmpaglifloz/Linaglip/Metformin12$6,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$707$838,328743 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Trijardy Xr$525$307,714411 claims
Novo NordiskOzempic$1,046$176,720161 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$487$49,78580 claims
BayerKerendia$223$32,02837 claims
PfizerEliquis$25$23,05731 claims
Johnson & JohnsonXarelto$585$11,12315 claims
Astellas Pharma US IncMyrbetriq$100$10,22623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Newton

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →